Guardant Health (NASDAQ:GH) Director Musa Tariq Sells 116 Shares

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 116 shares of the company’s stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $96.25, for a total value of $11,165.00. Following the completion of the transaction, the director owned 7,859 shares in the company, valued at approximately $756,428.75. The trade was a 1.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Musa Tariq also recently made the following trade(s):

• On Friday, October 17th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $66.95, for a total value of $7,766.20.
• On Wednesday, September 17th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $55.63, for a total value of $6,453.08.

Guardant Health Stock Up 6.6%

GH traded up $6.66 during trading hours on Friday, hitting $106.96. The stock had a trading volume of 1,006,505 shares, compared to its average volume of 2,477,703. Guardant Health, Inc. has a 1 year low of $29.91 and a 1 year high of $110.00. The company’s fifty day simple moving average is $73.93 and its 200 day simple moving average is $58.08. The stock has a market cap of $13.48 billion, a PE ratio of -33.39 and a beta of 1.56.

Guardant Health (NASDAQ:GH) last issued its earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.09. During the same quarter in the prior year, the business posted ($0.88) EPS. The firm’s revenue for the quarter was up 38.5% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current year.

Wall Street Analyst Weigh In

GH has been the topic of several recent research reports. Canaccord Genuity Group set a $100.00 target price on Guardant Health in a research report on Thursday, October 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a report on Wednesday, October 8th. Wolfe Research upgraded Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 target price for the company in a research note on Thursday, September 25th. William Blair reaffirmed an “outperform” rating on shares of Guardant Health in a report on Thursday, September 25th. Finally, Piper Sandler increased their price target on shares of Guardant Health from $60.00 to $90.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Twenty-three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Guardant Health has an average rating of “Moderate Buy” and an average price target of $77.14.

Hedge Funds Weigh In On Guardant Health

A number of institutional investors have recently added to or reduced their stakes in GH. Envestnet Asset Management Inc. boosted its position in shares of Guardant Health by 136.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 27,497 shares of the company’s stock valued at $1,171,000 after acquiring an additional 15,877 shares during the last quarter. CWM LLC raised its stake in Guardant Health by 180.3% in the first quarter. CWM LLC now owns 2,296 shares of the company’s stock valued at $98,000 after purchasing an additional 1,477 shares in the last quarter. Victory Capital Management Inc. lifted its position in Guardant Health by 1,410.0% during the first quarter. Victory Capital Management Inc. now owns 220,124 shares of the company’s stock valued at $9,377,000 after purchasing an additional 205,546 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Guardant Health during the first quarter valued at approximately $6,652,000. Finally, Legato Capital Management LLC bought a new position in shares of Guardant Health in the 1st quarter worth $1,523,000. 92.60% of the stock is currently owned by institutional investors.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.